Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Xenon (XENE), Hims & Hers Health (HIMS) and Merck & Company (MRK)

Tipranks - Tipranks - Wed Feb 25, 5:56AM CST

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Xenon (XENE – Research Report), Hims & Hers Health (HIMS – Research Report) and Merck & Company (MRK – Research Report).

Claim 50% Off TipRanks Premium

Xenon (XENE)

Needham analyst Serge Belanger maintained a Buy rating on Xenon today and set a price target of $55.00. The company’s shares closed last Monday at $42.72.

According to TipRanks.com, Belanger is a 5-star analyst with an average return of 11.3% and a 48.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, NewAmsterdam Pharma Company, and Amphastar Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xenon with a $55.63 average price target, a 32.3% upside from current levels. In a report released yesterday, Wolfe Research also initiated coverage with a Buy rating on the stock with a $60.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Hims & Hers Health (HIMS)

Canaccord Genuity analyst Maria Ripps maintained a Buy rating on Hims & Hers Health today and set a price target of $30.00. The company’s shares closed last Monday at $15.51, close to its 52-week low of $11.20.

According to TipRanks.com, Ripps is a 5-star analyst with an average return of 15.5% and a 42.0% success rate. Ripps covers the NA sector, focusing on stocks such as Zillow Group Class A, Alphabet Class A, and Meta Platforms. ;'>

Currently, the analyst consensus on Hims & Hers Health is a Hold with an average price target of $30.53, which is a 93.3% upside from current levels. In a report released today, TipRanks – Google also upgraded the stock to Buy with a $17.50 price target.

Merck & Company (MRK)

Citi analyst Geoff Meacham maintained a Hold rating on Merck & Company today. The company’s shares closed last Monday at $123.82.

According to TipRanks.com, Meacham is a 5-star analyst with an average return of 10.6% and a 60.2% success rate. Meacham covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Amylyx Pharmaceuticals Inc, and Protagonist Therapeutics. ;'>

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $126.74.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).